FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Last) C/O BRI	1. Name and Address of Reporting Person* STEPHENSON BRIAN C (Last) (First) (Middle) C/O BRIDGEBIO PHARMA, INC. 421 KIPLING STREET						2. Issuer Name and Ticker or Trading Symbol BridgeBio Pharma, Inc. [BBIO] 3. Date of Earliest Transaction (Month/Day/Year) 05/01/2020 4. If Amendment, Date of Original Filed (Month/Day/Year)									all app Direct Office below	or r (give title		10% O Other (below)	wner specify
(Street) PALO A	Street) PALO ALTO CA 94301														X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(Sta	ate) (Z	Zip)																	
		Table	I - I	Non-Deriva	tive	Secur	rities	Acc	quir	ed, D	Disp	posed o	f, or I	Benefic	ially	Own	ed			
Date				2. Transaction Date (Month/Day/Ye	Execution		n Date	, T	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4 a			ind 5) Se Be		i. Amount of Securities Beneficially Dwned Following Reported			7. Nature of Indirect Beneficial Ownership (Instr. 4)	
					c	Code	v	Am	nount	(A) or (D)	Price	Trans		action(s) 3 and 4)	(,	(
Common	05/01/202	.0				S ⁽¹⁾		(6,000	D	\$29.11	\$29.1133(2)		324,316		D				
Common Stock				05/01/202	0				S ⁽¹⁾		1,200		D	\$29.8288(3)		323,116		D		
Common Stock				05/04/202	20			5				1,494	D	\$30.00	48 ⁽⁴⁾	321,622		D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	/e Conversion Date Execution Date, or Exercise (Month/Day/Year) if any				nsaction of the (Instr. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			Expiration Date (Month/Day/Year)			Amo Secu Unde Deriv Secu 3 and	rlying ative rity (Instr.	nt er		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		

Explanation of Responses:

- 1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2019.
- 2. Represents the weighted average sale price of the shares sold from \$28.71 to \$29.68 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 4.
- 3. Represents the weighted average sale price of the shares sold from \$29.71 to \$30.14 per share.
- 4. Represents the weighted average sale price of the shares sold from \$30.00 to \$30.02 per share.

Remarks:

Secretary, Treasurer and Chief Financial Officer

/s/ Tara Condon, Attorney-in-

05/04/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.